Scandinavian ChemoTech

Scandinavian ChemoTech concludes the year on a high note with the receival of intriguing case reports featuring Tumour Specific Electroporation (TSE). These reports, which comes from the University Hospital in Jodhpur, marks a significant milestone in advancing the understanding of TSE's real-world applications.

The decision to prioritise the analysis of these cases, over the expected reports from Malaysia and the Philippines, underscores the exceptional nature of the findings and their potential impact on the evolution of TSE as a prominent cancer treatment modality. It also shows our priority to support the clinical and commercial development of our main human care market, India. A critical factor influencing the timelines of case reports is the ownership of data, primarily vested in oncology institutions or hospitals rather than within ChemoTech.

In the case reports, a reduction in tumour volume was observed in treatment-resistant cancers, especially in patients with significantly diminished life expectancy, which provides compelling evidence of TSE's efficacy. These findings suggest the potential benefits of integrating TSE into earlier and curative lines of therapy, showcasing its promise in challenging clinical scenarios.

This realization positions TSE as a pivotal consideration in Tumour boards for the multidisciplinary treatment of locally advanced solid tumours. As the company prepares to delve into the Malaysian and Philippine TSE case data, this success fuels optimism for the continued advancement of TSE in the coming year.

"The real-world data from palliative care indicates Tumour Specific Electroporation's true potential, illuminating its role beyond symptomatic relief. This revelation attempts to position TSE as a transformative force in curative lines of therapy, which needs further validation in clinical studies." - Dr. Suhail Mufti, Medical Director, Scandinavian ChemoTech

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.